Related Experiment Video
Updated: Jun 7, 2025
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.5K
Increased Risk of Hypoglycemia Following Roux-en-Y Gastric Bypass Surgery in Patients Without Diabetes: a Propensity
Eman A Toraih1,2, Mohamed Doma3, Aria Kaur Atwal4
1Tulane University, New Orleans, LA, USA. etoraih@tulane.edu.
Obesity Surgery
|November 12, 2024
Summary
Roux-en-Y gastric bypass (RYGB) surgery significantly increases hypoglycemia risk in non-diabetic obese patients. Close monitoring is crucial post-surgery to manage this elevated risk.
Area of Science:
- Bariatric Surgery
- Endocrinology
- Metabolic Disorders
Background:
- Roux-en-Y gastric bypass (RYGB) is effective for obesity but long-term hypoglycemia risk in non-diabetic patients is unclear.
- This study investigates hypoglycemia prevalence after RYGB in obese patients without prior diabetes.
Purpose of the Study:
- To determine the incidence and long-term risk of hypoglycemia following RYGB surgery.
- To assess the association between RYGB and hypoglycemia in a non-diabetic obese population.
Main Methods:
- Retrospective cohort study using the TriNetX database.
- 15,085 RYGB patients and 3,200,074 controls (obese, no diabetes, no GLP-1 use).
- Propensity score matching, Cox regression, and time-series analysis to evaluate hypoglycemia incidence (ICD-10 codes or glucose ≤70 mg/dL).
Main Results:
- RYGB patients had a significantly higher risk of hypoglycemia (18.70%) versus controls (3.80%) (HR 4.3).
- Post-matching, RYGB group still showed elevated risk (18.70% vs 5.0%, HR 3.7).
- Hypoglycemia risk remained elevated long-term post-RYGB, with HRs from 5.37 at 1 week to 3.75 at 10 years.
Conclusions:
- RYGB surgery is linked to a substantially increased short-term and long-term hypoglycemia risk in obese patients without diabetes.
- Routine monitoring and management of hypoglycemia are essential for patients post-RYGB, irrespective of pre-existing diabetes.
Related Concept Videos
01:15Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
01:16Insulin: Dosing Regimen and Adverse Effects
146
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
146
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
01:06Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141
01:22Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
01:24Glucagon-like Receptor Agonists
300
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300